Skip to main content

Angel García Jiménez

Institutions of which they are part

Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Angel García Jiménez

Institutions of which they are part

Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Papel de HER3 en la carcinogénesis de tumores de mama y endometrio. Búsqueda de nuevos factores predictivios de respuesta a tratamientos anti-HER

IP: Javier Hernandez Losa
Collaborators: Angel García Jiménez, Vicente Peg Camara
Funding agency: Fundación Invest. Médica Mutua Madrileña
Funding: 49200
Reference: FMM2009/02
Duration: 03/08/2009 - 02/08/2012

Patologia Molecular

IP: Santiago Ramon y Cajal Agüeras
Collaborators: Maria Rosa Somoza Lopez de Haro, Angel García Jiménez, Teresa Moline Marimon, Carmela Iglesias i Felip, Javier Hernandez Losa, Vicente Peg Camara, Stefania Landolfi , Trond Aasen
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 41600
Reference: 2009 SGR 756
Duration: 01/01/2010 - 30/04/2014

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un papel de 297 secuencias diferencialmente expresadas halladas por hibridación de Microarrays.

IP: Angel García Jiménez
Collaborators: Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Instituto de Salud Carlos III
Funding: 65435
Reference: PI020733
Duration: 06/11/2002 - 30/06/2006

Estudio e identificación de nuevos genes de senescencia y factores pivotales o comodines en señalización celular, angiogénesis e invasividad en carcinomas humanos: correlación clínico-patológica

IP: Santiago Ramon y Cajal Agüeras
Collaborators: Matilde Lleonart Pajarin, Angel García Jiménez, Josep Castellví Vives, Javier Hernandez Losa
Funding agency: Instituto de Salud Carlos III
Funding: 102340
Reference: PI050818
Duration: 01/01/2006 - 31/12/2009

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Sonia  Monreal  Clua

Sonia Monreal Clua

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Rosanna Paciucci Barzanti

Rosanna Paciucci Barzanti

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Pablo Vilalta Gras

Pablo Vilalta Gras

Zelador/a
General Services and Infrastructure
Manager
Read more
Carmen Sanchez Suarez

Carmen Sanchez Suarez

Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.